Skip to Content

Zecuity Approval History

  • FDA approved: Yes (First approved January 17th, 2013)
  • Brand name: Zecuity
  • Generic name: sumatriptan
  • Dosage form: Transdermal Patch
  • Previous name: Zelrix
  • Company: NuPathe Inc.
  • Treatment for: Migraine

Zecuity (sumatriptan iontophoretic transdermal system) is a serotonin (5HT) 1b/1d receptor agonist (triptan) indicated for the acute treatment of migraine.

Development History and FDA Approval Process for Zecuity

Jan 18, 2013Approval NuPathe's Zecuity Approved by the FDA for the Acute Treatment of Migraine
Aug 30, 2011FDA Requests Additional Information Regarding NuPathe's Migraine Patch in Complete Response Letter

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.